Saltar al contenido
Merck

P1636

Phenobarbital

GABA activator, powder

Sinónimos:

5-Ethyl-5-phenyl-2,4,6-pyrimidinetrione, 5-Ethyl-5-phenylbarbituric acid, Luminal

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Todas las fotos(3)

About This Item

Fórmula empírica (notación de Hill):
C12H12N2O3
Número CAS:
50-06-6
Peso molecular:
232.24
NACRES:
NA.77
PubChem Substance ID:
24898226
UNSPSC Code:
12352200
EC Number:
200-007-0
MDL number:
MFCD00066494
Beilstein/REAXYS Number:
233363

Nombre del producto

Phenobarbital,

InChI

1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)

SMILES string

CCC1(C(=O)NC(=O)NC1=O)c2ccccc2

InChI key

DDBREPKUVSBGFI-UHFFFAOYSA-N

form

powder

drug control

USDEA Schedule IV; Home Office Schedule 3; psychotrope (France); kontrollierte Droge in Deutschland; regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal); Pszichotróp anyag / Psychotropic Substance (Hungary), 78/2022. (XII. 28.) BM rendelet
kontrollierte Droge in Deutschland

Quality Level

200

originator

Bayer

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Biochem/physiol Actions

Anesthetic; sedative; hypnotic; anticonvulsant

Features and Benefits

This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

German
Dieses Produkt fällt unter das Betäubungsmittelgesetz (BtMG). Für eine Bestellung dieses Produktes ist eine Erlaubnis nach § 3 BtMG zwingend erforderlich, es sei denn, es greift eine Ausnahme von der Erlaubnispflicht nach § 4 oder § 26 BtMG.

English
This product is subject to the German Narcotics Act. A permit under Section 3 of the German Narcotics Act is mandatory for ordering this product unless an exemption from the permit requirement under Section 4 or Section 26 of the German Narcotics Act applies.

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Carc. 2 - Repr. 1B - Skin Sens. 1

Clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000489350
0000489350
0000476654
0000476654
0000467837

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Noura M Darwish et al.
Molecules (Basel, Switzerland), 27(9) (2022-05-15)
Hepatocellular carcinoma (HCC) is a common type of liver cancer and is a leading cause of death worldwide. Signal transducer and activator of transcription 3 (STAT3) is involved in HCC progression, migration, and suppression of apoptosis. This study investigates the
Peter J West et al.
Experimental neurology, 349, 113954-113954 (2021-12-20)
The discovery and development of novel antiseizure drugs (ASDs) that are effective in controlling pharmacoresistant spontaneous recurrent seizures (SRSs) continues to represent a significant unmet clinical need. The Epilepsy Therapy Screening Program (ETSP) has undertaken efforts to address this need
Melissa Barker-Haliski et al.
Epilepsia, 62(7), 1677-1688 (2021-06-04)
The kainic acid (KA)-induced status epilepticus (SE) model in rats is a well-defined model of epileptogenesis. This model closely recapitulates many of the clinical and pathological characteristics of human temporal lobe epilepsy (TLE) that arise following SE or another neurological
M Lundqvist et al.
Acta paediatrica (Oslo, Norway : 1992), 102(9), 863-867 (2013-06-07)
Treatment of neonatal seizures still relies primarily on phenobarbital, despite an estimated efficacy of less than 50% and concern over neurodegenerative side effects. The objective of this study was to evaluate the efficacy and safety of lidocaine as second-line treatment
Martin J Brodie et al.
Epilepsia, 53 Suppl 8, 40-46 (2012-12-12)
This article reviews the current position of phenobarbital using articles published since 2000 and speculates on its likely future contribution to epilepsy care. Over the last decade there have been no major double-blind randomized placebo-controlled or comparative trials with phenobarbital.
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico